Aileron Therapeutics Croissance future

Future contrôle des critères 0/6

Les bénéfices de Aileron Therapeutics devraient diminuer de 9.8% par an. Le BPA devrait augmenter de 3.4% par an.

Informations clés

-9.8%

Taux de croissance des bénéfices

3.4%

Taux de croissance du BPA

Biotechs croissance des bénéfices	28.4%
Taux de croissance des recettes	n/a
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aug 18

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Dec 30

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:ALRN - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-43	N/A	N/A	2
12/31/2025	N/A	-36	N/A	N/A	2
12/31/2024	N/A	-24	N/A	N/A	2
9/30/2024	N/A	-29	-28	-28	N/A
6/30/2024	N/A	-25	-26	-26	N/A
3/31/2024	N/A	-18	-20	-20	N/A
12/31/2023	N/A	-16	-20	-20	N/A
9/30/2023	N/A	-13	-14	-14	N/A
6/30/2023	N/A	-17	-19	-19	N/A
3/31/2023	N/A	-24	-22	-22	N/A
12/31/2022	N/A	-27	-25	-25	N/A
9/30/2022	N/A	-30	-27	-27	N/A
6/30/2022	N/A	-30	-27	-27	N/A
3/31/2022	N/A	-28	-25	-25	N/A
12/31/2021	N/A	-26	-24	-24	N/A
9/30/2021	N/A	-24	-22	-22	N/A
6/30/2021	N/A	-23	-20	-20	N/A
3/31/2021	N/A	-21	-21	-21	N/A
12/31/2020	N/A	-21	-20	-20	N/A
9/30/2020	N/A	-23	-22	-22	N/A
6/30/2020	N/A	-26	-24	-24	N/A
3/31/2020	N/A	-29	-25	-25	N/A
12/31/2019	N/A	-29	-27	-26	N/A
9/30/2019	N/A	-29	-29	-27	N/A
6/30/2019	N/A	-29	-31	-27	N/A
3/31/2019	N/A	-31	-33	-28	N/A
12/31/2018	N/A	-32	-32	-28	N/A
9/30/2018	N/A	-31	-30	-27	N/A
6/30/2018	N/A	-30	N/A	-25	N/A
3/31/2018	N/A	-26	N/A	-22	N/A
12/31/2017	N/A	-23	N/A	-21	N/A
9/30/2017	N/A	-20	N/A	-19	N/A
6/30/2017	N/A	-18	N/A	-18	N/A
3/31/2017	N/A	-19	N/A	-17	N/A
12/31/2016	N/A	-18	N/A	-15	N/A
9/30/2016	N/A	-17	N/A	-14	N/A
6/30/2016	N/A	-16	N/A	-12	N/A
3/31/2016	N/A	-14	N/A	-12	N/A
12/31/2015	N/A	-13	N/A	-12	N/A
9/30/2015	N/A	-13	N/A	-13	N/A
6/30/2015	N/A	-13	N/A	-12	N/A
3/31/2015	N/A	-15	N/A	-15	N/A
12/31/2014	N/A	-16	N/A	-17	N/A
12/31/2013	22	0	N/A	-14	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: ALRN devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: ALRN devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: ALRN devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: Données insuffisantes pour déterminer si les revenus de ALRN devraient croître plus rapidement que le marché US.

Croissance élevée des revenus: ALRN ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de ALRN devrait être élevé dans 3 ans

Aileron Therapeutics Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased by 44% to US$13.00

Price target decreased to US$2.00

Price target decreased to US$2.00

Recent updates

New major risk - Financial position

Aileron Therapeutics Announces Positive Topline Data from Cohort 2 of the Phase 1b Clinical Trial of LTI-03 in Idiopathic Pulmonary Fibrosis (IPF)

New major risk - Share price stability

New minor risk - Share price stability

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Price target increased by 44% to US$13.00

Aileron Therapeutics, Inc. has filed a Follow-on Equity Offering in the amount of $20 million.

Aileron Therapeutics, Inc. announced delayed annual 10-K filing

Aileron Therapeutics, Inc. Announces CFO Changes

Aileron Therapeutics, Inc. Announces CEO Changes

Aileron Therapeutics, Inc., Annual General Meeting, Feb 28, 2024

Aileron Therapeutics Receives Non-Compliance Notice from Nasdaq

New major risk - Share price stability

New major risk - Revenue and earnings growth

New minor risk - Share price stability

New minor risk - Shareholder dilution

Aileron Therapeutics, Inc. (NasdaqCM:ALRN) acquired Lung Therapeutics, Inc.

Aileron Therapeutics, Inc. announced that it expects to receive $16.4 million in funding from Nantahala Capital Management, LLC and other investors

Aileron Therapeutics Regains Compliance with Nasdaq Listing Requirements

Insufficient new directors

Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from Chemotherapy-Induced Damage at the European Society for Dermatological Research Annual Meeting 2022

Companies Like Aileron Therapeutics (NASDAQ:ALRN) Could Be Quite Risky

Aileron Therapeutics Outlines Strategy to Strengthen Phase 1b Clinical Trial of ALRN-6924 in Patients with p53-Mutated Breast Cancer

Insufficient new directors

Insufficient new directors

Aileron Therapeutics Announces Interim Data from Phase 1b Chemoprotection Trial of ALRN 6924 in Patients with p53-Mutated Non-Small Cell Lung Cancer (NSCLC) and Confirms Development Path for ALRN-6924 Focused on p53-Mutated Breast Cancer

Aileron Therapeutics Appoints Susan L. Drexler as Interim Chief Financial Officer

Aileron Therapeutics, Inc. Appoints Manuel Aivado as Principal Financial Officer and Principal Accounting Officer

Aileron Therapeutics Announces First Patients Treated in Phase 1B Trial of ALRN-6924 in Patients with p53-Mutated Neoadjuvant Breast Cancer

Aileron Therapeutics, Inc. Announces Resignation of Richard J. Wanstall as Chief Financial Officer, Effective from May 6, 2022

Price target decreased to US$2.00

Less than half of directors are independent

Is Aileron Therapeutics (NASDAQ:ALRN) In A Good Position To Deliver On Growth Plans?

Price target decreased to US$2.00

Less than half of directors are independent

Aileron Therapeutics: An Assessment On A Lottery Ticket

Aileron Therapeutics, Inc. Announces Initiation of Randomized, Double-Blind, Placebo-Controlled Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics: Solving Chemotherapy's Toxicity

Aileron Therapeutics, Inc. Announces Enrollment Expansion for Upcoming Phase 1b Clinical Trial of ALRN-6924 in Patients with Advanced Non-Small Cell Lung Cancer

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $35.894081 million.

Aileron Therapeutics +31% on insider buying more shares

Aileron raises $40M via equity offering

Aileron Therapeutics EPS in-line

Aileron Therapeutics Announces Proof-of-Concept Data for ALRN-6924 to be Featured in Late-Breaking Presentation at EORTC-NCI-AACR Annual Symposium

Aileron Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $0.762 million.

Aileron Therapeutics, Inc. announced that it expects to receive $15 million in funding from Lincoln Park Capital, LLC

Aileron Therapeutics, Inc.(NasdaqCM:ALRN) dropped from Russell Microcap Value Index

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance